WideCells Group


WideCells Group PLC Celebrates its Five-Year Anniversary

WideCells Group | WideCells Group PLC

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is delighted to announce its five-year anniversary today. 
 

WideCells Group was established in order to transform the stem cell industry by creating the first end-to-end service solutions to make stem cell treatment accessible and affordable globally.  Having recognised a need and identified an opportunity to change the way in which stem cell services are provided globally, Chief Executive Officer João Andrade and Chief Operating Officer Lopes Gil founded the company.  Since its inception, WideCells Group has made formidable progress in creating a dynamic, revenue generative business, which is now listed on the London Stock Exchange.   The significant progress made by the Group has resulted in WideCells Group being ranked as the 21st most disruptive company globally by DISRUPT 100 and being nominated as the Life Sciences IPO of the Year 2016 by Biotech & Money.

The Group’s service offering spans three synergistic divisions:

CellPlan Limited has successfully created and launched the world’s first stem cell healthcare insurance plan – CellPlan.  Recognising that whilst over 3 million people worldwide have paid c.£2,000 to store stem cells, the Group discovered that many were unaware that the cost to use stem cells in treatment can be up to £300,000.  Accordingly, the Group set out to remove cost barriers by creating CellPlan, which for an average price of £170 per annum provides financial cover for medical treatment, travel and accommodation expenses, an expert medical opinion and a concierge service to manage the stem cell treatment process.  The product is now available for purchase in the UK having secured strategic commercial agreements with the UK’s largest private human tissue storage facility Biovault Technical Ltd (‘Biovault’).  The Company is also due to launch an e-commerce platform shortly and has signed an agreement to supply customers in Brazil via Hemocord Clinica Medica Ltd, a world-class leader in cord blood storage.

WideCells Group division ('WideCells') is focussed on stem cell storage and processing and also undertakes pioneering stem cell research.  The Group has founded the Institute of Stem Cell Technology, which is based in the University of Manchester Innovation Centre.  This boasts a world-class laboratory and international cryogenics facility.   The Group also has a licensing agreement with an established stem cell storage and processing facility in São Paulo, Brazil, which has been in operation since 2012 and has a client base of circa 400 clients ('WideCells Brasil').  The storage facility in the UK allows the Group to target the European and Middle Eastern markets, whilst WideCells Brasil provides exposure to the rapidly growing South American stem cell market.  Storage represents a crucial chain in the Groups “end-to-end” stem cell service model and this global model allows the Group to standardise the stem cell storage process with a transparent pricing model and level of quality.  The research arm of this division underpins the Group’s commitment to driving innovation and development within the stem cell industry. The Group has already secured a contract to undertake research work on behalf of Qigenix, a California-based clinical stage medical device company, testing a new laser technology designed to increase the homing and integration of stem cells.

WideAcademy, is the Group’s education and training division, which is being spearheaded by Alan Greenberg, the former Director of Education at Apple.  The Group is committed to creating a portal through which trustworthy, authentic and digestible educational content and courseware on stem cell treatment can be easily accessed.  Improved knowledge on stem cell technologies is expected to lead to increased uptake and development in the industry.  Further details relating to the commercial launch of this is expected later this year.

WideCells Group CEO, João Andrade, said, “Only when reflecting over the past five years can we truly appreciate the inflection point the Company is currently at.  It was nearly one year ago today that we listed on the London Stock Exchange, having raised £2 million to create and develop the achievements that currently surround us.  Our focus has changed from product development to revenue generation as we have launched the world’s first stem cell insurance plan, signed deals with cord blood banks across the world, secured contracts to undertake pioneering stem cell research and ultimately built our presence across the globe.  We now look forward to rapidly scaling up our service reach and building revenues.

“Our aim has always been to educate the public in stem cell technologies and medical options that many may be unaware of, and to make such stem cell treatments affordable and accessible.  I believe we are now starting to see real change in this respect; the global stem cell industry is now worth in excess of US$100 billion and continuing to grow.  Of course, the driving force behind all that we have achieved to date has been our world-class Board and management team that has grown both in size and experience since the Company began.  Their commitment to achieving a better medical future is at the heart of everything we do and accordingly, I would like to thank them, together with our shareholders, for their continued hard work and dedication.  We have built a company which I believe is set to transform not only the stem cell industry but the future medical landscape.  I believe this is only the beginning of a significant future ahead.”

**ENDS**

For further information, please visit the Company’s website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

WideCells Group

CEO – João Andrade

Tel:  +351 919 033 171

Smaller Company Capital Ltd

Broker – Jeremy Woodgate & Rupert Williams

Tel: +44 (0) 20 3651 2912

Shard Capital Partners LLP

Broker – Damon Heath & Erik Woolgar

Tel: +44 (0) 207 186 9950

St Brides Partners Ltd

PR – Charlotte Page & Olivia Vita

Tel: +44 (0) 20 7236 1177

Notes to Editors

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable.  In June 2017, the Group was ranked as the 21st most disruptive company globally by DISRUPT 100, an annual index celebrating the businesses with the most potential to influence, change or create new global markets.

With this in mind, it has created three divisions:

  • CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process
  • WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.
  • WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

Stem Cell Fast Facts:

  • Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow – WideCells will focus on promoting the collection and storage of this.
  • Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells
  • 82 illnesses can currently be treated using stem cell procedures
  • Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands